Analysis updated Sep 24, 2026 — scores and signals refreshed daily.
CRISPR THERAPEUTICS AG (CRSP) stock analysis — updated Sep 24, 2026: Q-Score 68/100 — Strong Buy. AI alpha score, Graham intrinsic value, ML forecast, technicals and insider activity.
Current Q-Score verdict: Strong Buy (68.0) (grade A). 38 signals analyzed (33 differentiated alt-data).
StoQuant's analysis of CRISPR THERAPEUTICS AG (CRSP) is refreshed every trading day. The Q-Score combines discounted cash flow valuation, earnings quality, competitive moat, analyst consensus, ML return forecasts, technical momentum and market sentiment into a single 0–100 composite. Insider transactions from SEC Form 4 filings, the Graham intrinsic value estimate and signal coverage are recomputed as new data arrives, so this page always reflects the latest available information.
CRSP stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-05-15 | $50.45 | $48.25 | $48.41 |
| 2026-05-28 | $57.24 | $52.38 | $56.38 |
| 2026-06-09 | $53.09 | $49.58 | $51.48 |
| 2026-06-22 | $56.08 | $54.08 | $54.36 |
| 2026-07-02 | $61.68 | $56.18 | $60.08 |
| 2026-07-15 | $51.49 | $49.92 | $51.37 |
| 2026-07-27 | $48.28 | $46.71 | $46.73 |
| 2026-08-06 | $53.11 | $51.51 | $51.64 |
| 2026-08-18 | $53.88 | $51.80 | $52.97 |
| 2026-08-28 | $59.37 | $57.10 | $57.72 |
| 2026-09-10 | $52.63 | $51.72 | $52.26 |
| 2026-09-22 | $60.72 | $57.64 | $59.03 |
How CRISPR THERAPEUTICS AG stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| AZN | AstraZeneca PLC | $290.7B | — |
| NVS | Novartis AG | $287.1B | — |
| NVO | Novo Nordisk A/S | $200.3B | — |
| SNY | Sanofi | $107.6B | — |
| GSK | GSK plc | $102.1B | — |
View all Health Care stocks by valuation and signals →
CRISPR THERAPEUTICS AG (CRSP) scores Strong Buy (68.0), and the composite conceals a 60-point disagreement between its dimensions. It is strongest on competitive moat at 98 and technicals at 98, and weakest on ML forecast at 40 and social sentiment at 38. A stock can carry competitive moat that high while social sentiment sits at 38; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 98 |
| technicals | 98 |
| analyst consensus | 67 |
| ML forecast | 40 |
| social sentiment | 38 |
StoQuant analyzes 38 signals (33 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on CRISPR THERAPEUTICS AG (CRSP): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CRSP"><img src="https://stoquant.com/badge/CRSP.svg" alt="CRISPR THERAPEUTICS AG (CRSP) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.